medigraphic.com

2013, Number 2

<< Back Next >>

Rev Cuba Endoc 2013; 24 (2)

Prevalence of diabetes mellitus and of altered glycemia on fasting in an area of the city of Sancti Spiritus

Bustillo SEE, Bustillo MEE, Pérez FY, Pérez SR, Brito GÁ, González IÁ, García CJ

Language: Spanish
References: 55
Page: 107-124
PDF size: 151.55 Kb.


ABSTRACT

Objectives: to determine the prevalence of non-ketoacidosis prone diabetes mellitus and of altered glycemia on fasting in the patients of 20 doctor's offices located in the northern area of the city of Sancti Spiritus.
Methods: the population for the analysis was taken from a cross-sectional study of 20 doctor's offices located in the northern health area of the city of Sancti Spiritus, which had been conducted from January 2006 to December 2010. In the previous research, the universe of study was the population aged 16 years and over attended by 20 randomly selected family doctor's offices (n=9 895 people) of whom 1 019 people had been studied. Most of the patients lived in the urban area of the city (93.62 %). There was then reconsidered whether this sample, previously studied through the Epinfo 6 program, Statcal module, would be suitable to attain the objective of the new analysis, and finally an estimated sample of 340 and 574 persons was obtained for a 95 % confidence interval and 99 % reliability index, respectively. This new analysis made it possible to reassess the information stored at the database.
Results: the global prevalence index of diabetes mellitus was 13.64 % (CI 95 %: 11.53-15.745). The diabetes type 2 patients and the normoweighted diabetics accounted for 10.4 % (CI 8.25-12.27 %) and 3.4 % (CI 95 %: 3.03-3.43 %) of the studied population, respectively. The frequency of diabetes mellitus type 2 increased from the age of 50 years on whereas females were slightly predominant (11.6 vs. 8.8 %). The altered glycemia on fasting was diagnosed in 25.22 % (CI 95 %: 19.91- 30.52 %), with predominance of this prediabetic condition in the studied urban population (26.2 % vs. 10.8 %).
Conclusions: the prevalence of diabetes mellitus and of altered glycemia on fasting was high in the population under study.


REFERENCES

  1. Whiting D, Guariguata L, Weil C, Shaw J. IDF Diabetes Atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94:311-21.

  2. Nicholson G, Hall GM. Diabetes mellitus: new drugs for a new epidemic. Br J Anaesth. 2011;107:65-73.

  3. Schulz LO, Bennett PH, Ravussin E, Kidd JR, Kidd KK, et al. Effects of traditional and western environments on prevalence of Type 2 Diabetes in Pima Indians in Mexico and the U.S. Diabetes Care. 2006;29:1866-71.

  4. Barcelo A, Rajpathak S. Incidence and prevalence of diabetes mellitus in the Americas. Pan Am J Public Health. 2001;10:300-8.

  5. Guzmán JR, Lyra R, Aguilar-Salinas CA, Cavalcanti S, Escaño F, Tambasia M, et al. Treatment of type 2 diabetes in Latin America: a consensus statement by the medical associations of 17 Latin American countries. Rev Panam Salud Pública. 2010;28:463-71.

  6. Guías ALAD de diagnóstico, control y tratamiento de la diabetes mellitus tipo 2. Grupo de trabajo ALAD. Rev Asoc Latinoam Diabetes. 2006;14:96-140.

  7. Permutt MA, Wasson J, Cox N. Genetic epidemiology of diabetes. J Clin Invest. 2005;115:1431-9.

  8. Diagnosis and Classification of Diabetes Mellitus. American Diabetes Association. Position Statement. Diabetes Care. 2013; Suppl 1:S67-S74.

  9. Vaxillaire M, Froguel P. Monogenic diabetes in the young, pharmacogenetics and relevance to multifactorial forms of type 2 diabetes. Endocrine Reviews. 2008;29:254-64.

  10. Barrio R. Diabetes monogénicas: enfoque diagnóstico y tipos más frecuentes. Av Diabetolol. 2007;23:333-40.

  11. Fender W, Borowiec M, Baranowska-Jazwiecka A, Szadkowska A, Skala- Zamorowska E, Deja G, et al. Prevalence of monogenic diabetes amongst Polish children after a nationwide genetic screening campaign. Diabetologia. 2012;55:2631-5.

  12. Nambam B, Aggarwal S, Jain A. Latent autoimmune diabetes in adults: a distinct but heterogeneous clinical entity. World J Diabetes. 2010;1:111-5.

  13. Grant SFA, Hakon Hakonarson H, Schwartz S. Can the genetics of type 1 and type 2 diabetes shed light on the genetics of latent autoimmune diabetes in adults? Endocrine Reviews. 2010;31:183-93.

  14. Bustillo Solano E, Pérez Francisco Y, Brito García A, González Iglesia A, Castañeda Montano D, Santos González M, et al. Síndrome metabólico, un problema de salud no diagnosticado. Rev Cubana Endocrinol. 2011;22:167-81.

  15. Morejón Giraldoni AF, Benet Rodríguez M, Díez y Martínez de la Cotera E, García Torres D, Salas Rodríguez V, Ordúñez García PO. Síndrome metabólico en un área de salud de Cienfuegos. Segunda medición de CARMEN. Finlay. 2011;1:6-14.

  16. Standards of medical care in diabetes. Position statement. American Diabetes Association-2011. Diabetes Care. 2011;34(Suppl 1):S11-S61.

  17. Álvarez S, Pérez Paz MJ, Marino H. Prevalencia de diabetes mellitus en la población adulta en un área de salud del municipio Santiago de Cuba. Rev Cubana Hig Epidemiol 1987;25:205-13.

  18. Pérez Rivero JL, Reguerira Naranjo JL, Hernández Hernández R. Caracterización de la diabetes mellitus en un área de salud. Rev Cubana Med Gen Integr [serie en Internet]. 2002 [citado 31 de octubre de 2012];18(4). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864- 21252002000400003&lng=es&nrm=iso

  19. Díaz Díaz O, Valenciaga Roríguez JL, Domínguez Alonso E. Comportamiento epidemiológico de la diabetes mellitus en el municipio de Güines: año 2002. Rev Cubana Hig Epidemiol [serie en Internet]. 2004 [citado 31 de octubre de 2012];42(1). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-30032004000100003 &lng=es&nrm=iso

  20. Ramírez Leyva E, Álvarez Aldana D, García Moreira R, Álvarez Fernández M, Rodríguez Bebert Y, Matos Valdivia Y. Diabetes mellitus en Ciego de Ávila: serie secular 1997-2008. Rev Cubana Endocrinol [serie en Internet]. 2009 [citado 31 de octubre de 2012];20(3). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561- 29532009000300004&lng=es&nrm=iso

  21. Asociación Latinoamericana de Diabetes. Epidemiología de la diabetes mellitus en Latinoamérica. En: Guías ALAD de diagnóstico, control y tratamiento de la diabetes mellitus tipo 2. Rev Asoc Latinoam Diabetes. 2000; Supl 1:1-79.

  22. Escobedo-de la Peña J, Buitrón-Granados LV, Ramírez-Martínez JC, Chavira- Mejía R, Schargrodsky H, Champagne BM. Diabetes in México. CARMELA study. Cir Cir. 2011;79:424-31.

  23. Ginter E, Simko V.Type 2 diabetes mellitus, pandemic in 21st century. Adv Exp Med Biol. 2012;771:42-50.

  24. Consenso Latinoamericano de la Asociación Latinoamericana de Diabetes (ALAD). Epidemiología, Diagnóstico, Control, Prevención y Tratamiento del Síndrome Metabólico en Adultos [homepage en Internet] [citado 7 de noviembre de 2012] Disponible en: http://www.aladlatinoamerica. org/index.php?option=com_content&view=article&id=255&Itemid=10 6/Documentos de consenso de la ALAD. SX. Metabólico en adultos.pdf

  25. Naik RG, Brooks-Worell BM, Palmer JP. Latent autoimmune diabetes in adults. J Clin Endocrinol Met. 2009;94:4635-44.

  26. Cabrera Rode E, Licea Puig ME. Nueva definición, prevalencia, caracterización y tratamiento de la diabetes autoinmune latente del adulto. Rev Cubana Endocrinol [serie en Internet]. 2008 [citado 7 de noviembre de 2012];19(3). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561- 29532008000300008&lng=es&nrm=iso&tlng=es

  27. Sørgjerd EP, Skorpen F, valøy K, Midthjell K, Grill V. Prevalence of ZnT8 antibody in relation to phenotype and SLC30A8 polymorphism in adult autoimmune diabetes. Results from the HUNT study, Norway. Autoimmunity. 2013;46:74-9.

  28. Calsolari MR, Rosário PW, Reis JS, Silva SC, Purisch S. Latent autoimmune diabetes of adult or slim type 2 diabetes mellitus? Arq Bras Endocrinol Metabol. 2008;52:315-21.

  29. Carlsson S, Midthjell K, Grill V. Influence of family history of diabetes on incidence and prevalence of latent autoimmune diabetes of the adult: results from the Nord-Trøndelag Health Study. Diabetes Care. 2007;30:3040-45.

  30. Poudel RR. Latent autoimmune diabetes of adults: from oral hypoglycemic agents to early insulin. Indian J Endocr Metab. 2012;16:S41-6.

  31. Szepietowska B, G³êbocka A, Puch U, Górska M, Szelachowska M. Latent autoimmune diabetes in adults in a population-based cohort of Polish patients with newly diagnosed diabetes mellitus. Arch Med Sci. 2012;8:491-5.

  32. Fourlanos S, Dotta F, Greenbaum CJ, Palmer JP, Rolandsson O, Colman P, et al. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia. 2005;48:2206-12.

  33. Yul Hwangbo, Jin Taek Kim, Eun Ky Kim, Ah Reum Khang, Tae Jung Oh, Hak Chul Jang, et al. Prevalence and clinical characteristics of recently diagnosed type 2 diabetes atients with positive anti-lutamic acid decarboxylase antibody. Diabetes Metab J. 2012;36:136-43.

  34. Borg H, Arnqvist HJ, Bjork E, Bolinder J, Eriksson JW, Nystrom L, et al. Evaluation of the new ADA and WHO criteria for classification of diabetes mellitus in young adult people (15-34 years) in the Diabetes Incidence Study in Sweden (DISS). Diabetologia. 2003;46:173-81.

  35. Xiuying QI, Sun J, Wang J, Peizhong PW, Zhongliang XU, Murphy M, et al. Prevalence and correlates of latent autoimmune diabetes in adults in Tianjin, China. A population-based cross-sectional study. Diabetes Care. 2011;34:66-70.

  36. Cabrera-Rode E, Perich P, Díaz-Horta O, Molina G, Suárez L, Tiberti C, et al. Diabetes autoinmune del adulto en diabéticos tipo 2: frecuencia y características. Rev Cubana Endocrinol. 2001;12:22-34.

  37. Cabrera-Rode E, Díaz-Horta O, Rendón A, Molina G, Vera M, Licea M, et al. Prevalence of islet cell antibodies (ICA) in diabetes mellitus and other diseases in Cubans. Autoimmunity. 1997;26:7-10.

  38. Cabrera-Rode E, Licea M, Molina G, Arranz C, Díaz-Horta O, Uriarte A. Inmunogenética y caracterización clínico metabólica en la diabetes mellitus no insulino dependiente de acuerdo con la presencia de anticuerpos antiislotes pancreáticos. Avances en Diabetología. 1995;10:101-10.

  39. Fourlanos S, Perry S, Stein MS, Stankovich J, Harrison LC, Colman PG. A Clinical screening tool identifies autoimmune diabetes in adults. Diabetes Care. 2006;29:970-5.

  40. Bellanne-Chantelot C, Dubois-Laforgue D, Velho G. Diagnosis and management of maturity-onset diabetes of the young. Timsit Treat Endocrinol. 2005;4:9-18.

  41. Furuzawa GK, Giuffrida FM, Oliveira CS, Chacra AR, Dib SA, Reis AF. Low prevalence of MODY2 and MODY3 mutations in Brazilian individuals with clinical MODY phenotype. Diabetes Res Clin Pract. 2008;81:12-4.

  42. DellaManna T, Silva MR, Chacra AR, Kunii IS, Rolim AL, Furuzawa G, Maciel RM, Reis AF. Clinical follow-up of two Brazilian subjects with glucokinase-MODY (MODY2) with description of a novel mutation. Arq Bras Endocrinol Metabol. 2012 Nov;56:490-5.

  43. Conesa González AI, González Calero TM. Aspectos más recientes en relación con la diabetes mellitus tipo MODY. Rev Cubana Endocrinol [serie en Internet]. 2012 [citado 26 de noviembre de 2012];23(2). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561 - 29532012000200008&lng=es&nrm=iso

  44. Hattersley A, Bruining J, Shield J, Njolstad P, Donaghue K. ISPAD Clinical Practice Consensus Guidelines 2006-2007. The diagnosis and management of monogenic diabetes in children. Pediatric Diabetes. 2006;7:352-60.

  45. Eide SA, Raeder H, Johansson S, Midthjell K, Søvik O, Njølstad PR. Molven Prevalence of HNF1A (MODY 3) mutations in a Norwegian population (the HUNT2 Study). Diabet Med. 2008;25:775-81.

  46. Murphy R, Ellard S, Hattersley AT. Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes. Nat Clin Pract Endocrinol Metab. 2008;4:200-13.

  47. Ramachandran A, Snehalatha C, Kapur A, Vijay V, Mohan V, Das AK, et al. High prevalence of diabetes and impaired glucose tolerance in India. National Urban Diabetes Survey. Diabetologia. 2001;44:1094-101.

  48. Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a highrisk state for diabetes development. Lancet. 2012; Jun 16;379:2279-90.

  49. Cowie CC, Rust KF, Ford ES, Eberhardt MS, Byrd-Holt DD, Li C, et al. Full accounting of diabetes and prediabetes in the U.S population in 1988-1994 and 2005-2006. Diabetes Care. 2009;32:287-94.

  50. Anjana RM, Pradeepa R, Deepa M, Datta M, Sudha V, Unnikrishnan R, et al; ICMRINDIAB Collaborative Study Group. Prevalence of diabetes and prediabetes (impaired fasting glucose and/or impaired glucose tolerance) in urban and rural India: phase I results of the I Council of Medical Research-INdia DIABetes (ICMRINDIAB) study. Diabetologia. 2011;54:3022-7.

  51. Di Flaviani A, Picconi F, Di Stefano P, Giordani I, Malandrucco I, Maggio P, et al. Impact of glycemic and blood pressure variability on surrogate measures of cardiovascular outcomes in type 2 diabetic patients. Diabetes Care. 2011;34:1605-9.

  52. Teramoto T, Shirai K, Daida H, Yamada N. Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study. Cardiovasc Diabetol. 2012;23:11-8.

  53. Farnier M, Retterstøl K, Steinmetz A, Császár A. Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease. Diab Vasc Dis Res. 2012;9:205-15.

  54. Redon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue J, et al. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J Am Coll Cardiol. 2012;59:74-83.

  55. Millán J, Alegría E, Guijarro C, Lozano JV, Vitale GC, González-Timón B, et al. Dyslipemia in diabetics treated with statins. Results of the Dyslipidemia International Study in Spain. Med Clin (Barc). 2012 Dec;12:S0025-7753.




2020     |     www.medigraphic.com